Document Detail

A prospective randomized trial of single- or dual-chamber implantable cardioverter-defibrillators to minimize inappropriate shock risk in primary sudden cardiac death prevention.
MedLine Citation:
PMID:  24928948     Owner:  NLM     Status:  Publisher    
AIMS: Dual-chamber implantable cardioverter-defibrillators (ICDs) may improve specificity and reduce the risk of inappropriate shocks, and enhance atrial arrhythmia (AT/AF) detection to permit stroke prevention compared with single-chamber ICDs, but at additional expense and risk.
METHODS AND RESULTS: Patients (n = 100) receiving primary prevention ICDs at two USA and two Israeli centres were randomized to dual-chamber or single-chamber devices between December 2008 and December 2010 and were followed for 1 year. Programming in both groups included: delayed detection to avoid therapy for non-sustained episodes; high detection cut-off rates to avoid treating slower, better tolerated arrhythmias; minimized right ventricular pacing; and routine use of supraventricular-ventricular tahcycardia discriminators and antitachycardia pacing. The primary outcome was the proportion of patients with inappropriate shocks. One patient in each group (2%) received inappropriate shocks (P = 1.00). Death occurred in two patients in the single-chamber arm, and in none of the patients in the dual-chamber arm (P = 0.15). New AT/AF was detected in 12 patients (24%) in the dual-chamber group, vs. no patients in the single-chamber group (P < 0.001). Among US participants, the mean cost of dual- vs. single-chamber ICD implantation was $16 579 vs. $14 249, respectively (P < 0.001); there was no difference in the quality of life (EQ-5D index difference 0.013, P = 0.769; EQ VAS difference 3.3, P = 0.49).
CONCLUSION: When optimal programming is utilized, inappropriate shocks are rare in primary prevention patients with both single- and dual-chamber ICDs. The routine use of dual-chamber ICDs increases the expense without reducing inappropriate shocks or improving the quality of life at 1 year.
TRIAL REGISTRATION: Identifier: NCT00787800.
Paul A Friedman; David Bradley; Celeste Koestler; Joshua Slusser; David Hodge; Kent Bailey; Fred Kusumoto; Thomas M Munger; Arie Militanu; Michael Glikson
Related Documents :
23541428 - Outcome of concomitant cox-maze iii procedure using an argon-based cryosurgical system:...
24848528 - Vertical rectus abdominis myocutaneous flap and quality of life following abdominoperin...
22931868 - Functional results and quality of life after retrosigmoid vestibular neurectomy in pati...
23144438 - The postoperative analgesic efficacy of preperitoneal continuous wound infusion compare...
11454508 - Effects of preoperative octreotide treatment on different subtypes of 90 gh-secreting p...
23813988 - Differences in outcome and predictors between ischemic and intracerebral hemorrhage: th...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-13
Journal Detail:
Title:  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology     Volume:  -     ISSN:  1532-2092     ISO Abbreviation:  Europace     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883649     Medline TA:  Europace     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Canc...
Next Document:  Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Over...